Holen Sie sich die Stockscreener-App
1.31
5.76%
-0.08
Schlusskurs vom Vortag:
$1.39
Offen:
$1.38
24-Stunden-Volumen:
60,022
Relative Volume:
0.12
Marktkapitalisierung:
$34.90M
Einnahmen:
$59.07M
Nettoeinkommen (Verlust:
$-52.66M
KGV:
-0.6517
EPS:
-2.01
Netto-Cashflow:
$-40.16M
1W Leistung:
-2.24%
1M Leistung:
-55.89%
6M Leistung:
-82.76%
1J Leistung:
-86.99%
1-Tages-Spanne:
$1.30
$1.38
1-Wochen-Bereich:
$1.255
$1.44
52-Wochen-Spanne:
$1.255
$11.30
Cvrx Inc Stock (CVRX) Company Profile
Firmenname
Cvrx Inc
Sektor
Branche
Telefon
(763) 416-2850
Adresse
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
1.31 | 34.90M | 59.07M | -52.66M | -40.16M | -2.01 |
ABT
Abbott Laboratories
|
98.61 | 170.62B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
93.39 | 119.46B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.48 | 112.95B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.14 | 63.97B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.72 | 50.56B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-07 | Herabstufung | Craig Hallum | Buy → Hold |
| 2026-08-07 | Herabstufung | Lake Street | Buy → Hold |
| 2026-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-05-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-01-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-11 | Bestätigt | Lake Street | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2024-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Lake Street | Buy |
| 2022-07-18 | Eingeleitet | Craig Hallum | Buy |
| 2021-07-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-26 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-26 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cvrx Inc Aktie (CVRX) Neueste Nachrichten
Canaccord keeps Buy for CVRx stock as CVRx appoints John Landry CFO - AD HOC NEWS
Form 13D/A CVRx For: 2 October By Investing.com - Investing.com Nigeria
Share sales take a holder below 5% ownership of CVRx (CVRX). - Stock Titan
Why Is CVRx (NASDAQ:CVRX) Suddenly a Must-Watch Smallcap Stocks Name? - Kalkine Media
CVRx Inc. (CVRX) Stock Price | Live Quotes & Charts | NASDAQ - stockstotrade.com
CVRx, Inc. (CVRX) stock price, news, quote and history - Yahoo Finance UK
CVRx, Inc. (CVRX) stock price, news, quote and history - Yahoo Finance Australia
CVRx stock holds steady as investors eye latest revenue growth - AD HOC NEWS
CVRx stock dips as Cantor slashes price target after guidance update - AD HOC NEWS
Beta Bionics, Inc. (BBNX) Surges 15.3%: Is This an Indication of Further Gains? - Yahoo Finance
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop - PR Newswire
CVRX stock edges higher as investors watch neuromodulation growth - ad-hoc-news.de
CVRX stock benefits as Barostim heart failure therapy gains new Medicare Advantage coverage - ad-hoc-news.de
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc.CVRX - PR Newswire
CVRx Secures Devoted Health Coverage for Barostim Therapy - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Shareholders to Connect - accessnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims - PR Newswire
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Shareholders to Learn More About the Investigation - accessnewswire.com
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX) - qz.com
CVRx has an activist investor urging it to get acquired - MassDevice
CVRx Responds to Letter from Pointillist Family Office - marketscreener.com
CVRx Responds to Letter from Pointillist Family Office - GlobeNewswire
CVRx responds to shareholder letter on company valuation - Investing.com
CVRx earns new Medicare Advantage coverage policy for Barostim - MassDevice
CVRx Inc. Faces Securities Law Investigation Over Revenue Guidance Cut and DOJ Demand - kalkine.ca
Investor holding 5.5% of CVRx urges board to pursue sale By Investing.com - Investing.com Nigeria
Investor holding 5.5% of CVRx urges board to pursue sale By Investing.com - Investing.com Canada
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy - The Manila Times
Jorey Chernett, Owner of More Than 5.5% of Ou - Moomoo
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy - GlobeNewswire
New CVRx (NASDAQ: CVRX) investor urges board to prioritize a sale - Stock Titan
Jorey Chernett Urges Board to Launch Sale Process - marketscreener.com
Jorey Chernett Pushes for Sale at CVRx with 5.5% Stake - TradingView
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Investigation launched into CVRx over DOJ probe, sales issues, and sudden CRO firing. - Pluang
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
CVRx (CVRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Law firm investigates CVRx for possible securit... - Pluang
Cantor Fitzgerald Maintains CVRx Inc(CVRX.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Cantor cuts CVRx stock price target on sales execution challenges By Investing.com - Investing.com South Africa
CVRX Q2 2026 Earnings: Modest EPS Beat Offset by 10.71% Share SlidePositive Surprise Momentum - vinanet.vn
Cantor cuts CVRx stock price target on sales execution challenges - Investing.com
Cantor cuts CVRx stock price target on sales execution challenges By Investing.com - Investing.com India
Cantor cuts CVRx stock price target on sales execution challenges By Investing.com - Investing.com Canada
Finanzdaten der Cvrx Inc-Aktie (CVRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cvrx Inc-Aktie (CVRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Binkowski Brent | CHIEF OPERATING OFFICER |
Aug 12 '26 |
Sale |
2.55 |
1,309 |
3,338 |
30,291 |
| Adamson Philip B. | Chief Medical Officer |
Mar 02 '26 |
Sale |
7.90 |
1,262 |
9,973 |
61,578 |
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
1.27%
4.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):